February 28 – March 1, 2017 | San Francisco

 

 

 

 

Day One
Tuesday, February 28, 2017

Day Two
Wednesday, March 1, 2017

08.00
Registration

08.50
Co-Chairs’ Opening Remarks

  • Kenneth W. Mahaffey M.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. Wasserman M.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

Synopsis

  • Outlining the state of the state in cardiovascular therapeutic development – recent developments

Novel Pathways That Intersect Between CVD, Diabetes & Diabetic Kidney Disease

09.00
SGLT2 Inhibitors: Cardiorenal Protection & Possible Mechanisms

  • Mark C. Kowala Ph.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team, Eli Lilly and Company

Synopsis

  • Understanding the potential mechanism of action of SGLT2 inhibitors in cardiovascular risk reduction
  • Exploring the possibilities of cardiometabolic therapeutic approaches

09.30
Is Metformin a Cardiovascular Drug? – An Overview

  • Gregory Schwartz M.D., Ph.D, Professor of Medicine (Cardiology), University of Colorado, Denver

Synopsis

  • Analyzing the clinical evidence supporting a possible cardiovascular benefit of metformin
  • Evaluating the experimental evidence supporting a possible cardiovascular benefit of metformin
  • Designing a clinical trial to test the hypothesis that metformin reduces ischemic cardiovascular events

10.00
Morning Refreshments & Speed Networking

11.00
An Update on the Current Status of PCSK9 Inhibitor Development

  • Jay Edelberg M.D., Ph.D, VP & Head, Cardiovascular Development, Sanofi

Synopsis

  • Briefly outlining the history of discovery and development to date
  • Exploring the key details of the latest outcomes trial

11.30
ZD100: A Novel Designer Particulate Guanylyl Cyclase Receptor-An Activating Peptide for Cardiometabolic Disease

  • John C. Burnett Jr M.D., Marriott Family Professor of Cardiovascular Research, Division Of Cardiovascular Diseases, Mayo Clinic

Synopsis

  • Exploring how the natriuretic peptide/pGC-A/cGMP pathway represents an unprecedented opportunity to mediate cardiorenal and metabolic protection
  • Providing proof of concept for a role for pGC-A activators in cardiometabolic disease – how preclinical investigations of pGC-A demonstrate pleotropic actions on multiple organ systems and cell types
  • Understanding why ZD 100 represents a best in the class of pGC-A activating peptides
  • Presenting the results from the first in-human study

12.00
Lunch & Networking

13.00
Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

  • Gregory Schwartz M.D., Ph.D, Professor of Medicine (Cardiology), University of Colorado, Denver
  • Jay Edelberg M.D., Ph.D, VP & Head, Cardiovascular Development, Sanofi
  • John C. Burnett Jr M.D., Marriott Family Professor of Cardiovascular Research, Division Of Cardiovascular Diseases, Mayo Clinic
  • Mark C. Kowala Ph.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team, Eli Lilly and Company
  • Matthew T. Roe M.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, , Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)

Synopsis

  • Evaluating what these pharmacotherapeutic intersections mean for the development of future targets for cardiovascular therapeutics
  • Discussing drug safety and regulatory approval in this space
  • Assessing the response of payers, patients and practitioners
  • Outlining where we are and where we are going – important learnings to date and perspective on future directions

Therapeutic Developments in the Treatment of Heart Failure

13.45
Breakthroughs in Heart Failure Treatment – Single-Dose Treatments

Synopsis

  • Sharing Renova Therapeutics’ transformational therapy developments for congestive heart failure and acute decompensated heart failure
    • RT-100: AC6 gene therapy
    • RT-400: Stresscopin peptide infusion
  • Understanding single-dose treatment for heart failure – Renova’s second-generation gene therapy products

14.15
The Role of sGC Stimulators in the Treatment of Heart Failure

  • Joerg Koglin M.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research, Merck

Synopsis

  • Understanding the rationale and science behind soluble guanylate cyclase stimulation
  • Dosing finding and go-to-Phase-3 for Vericiguat
  • Looking into the Phase 3 approach in VICTORIA

14.45
Afternoon Refreshments & Networking

15.15
Targeting Mitochondria to Improve Outcomes in Heart Failure

  • Jim Carr VP, Clinical Development, Stealth BioTherapeutics

Synopsis

  • Evaluating the role of mitochondria in heart failure
  • Targeting end organ dysfunction in HF patients
  • Assessing clinical development concepts in targeting mitochondria

15.45
Pioneering Precision Cardiovascular Medicine

  • Eric Green M.D., Ph.D, Head of Translational Research, MyoKardia, Inc.

Synopsis

  • Developing an integrated genotype/phenotype precision medicine platform for cardiovascular disease
  • Overviewing the first investigational drug discovered with this platform, MYK-461, currently in phase 2 studies for patients with symptomatic obstructive hypertrophic cardiomyopathy
  • Exploring a  second investigational drug, MYK-491, being developed for patients with dilated cardiomyopathy, which will be initiating clinical trials in 2017

16.15
Panel Discussion: What’s Next in the Treatment of Heart Failure?

  • Curtis Rambaran M.D., FAHA, FRCP, Head of Cardiovascular Translational Medicine, Daiichi-Sankyo
  • Jack W. Reich Ph.D, CEO & Co-Founder, Renova Therapeutics
  • Jim Carr VP, Clinical Development, Stealth BioTherapeutics
  • Joerg Koglin M.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research, Merck
  • Thomas Povsic M.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist, Duke Clinical Research Institute (DCRI)

Synopsis

  • Exploring novel thinking and the latest approaches to therapeutics in the treatment of heart failure
  • Discussing therapeutics safety and regulatory approval in this space
  • Analyzing the next steps in developing an increasingly efficient treatment to heart failure

17.00
Co-Chairs’ Closing Remarks

  • Kenneth W. Mahaffey M.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. Wasserman M.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

17.15
Close of Conference Day One